New & next-generation GLP-1 weight-loss drugs (2026): orforglipron, retatrutide & more

The medicines behind the weight-loss boom — GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro and Zepbound — are evolving quickly. In 2025–2026 the first oral GLP-1 pill reached the market and several next-generation injectables moved through late-stage trials.

This page is a plain-language tracker of what is newly approved and what is still investigational, with the development stage for each. It is general information, not medical advice, and it does not recommend any drug. Investigational drugs are not available by prescription. Information is current as of June 2026 and the landscape changes often — always confirm status with the FDA and a licensed clinician.

Orforglipron (Foundayo) — the first oral GLP-1 pill (approved)

Status: FDA-approved (April 1, 2026). Maker: Eli Lilly. Class: oral, small-molecule (non-peptide) GLP-1 receptor agonist. See our page: Foundayo (orforglipron).

Orforglipron, sold as Foundayo, is the first GLP-1 medicine for weight management that comes as a daily pill rather than a weekly injection — and, unlike the oral form of semaglutide, it can be taken at any time of day with or without food or water. It is approved for adults with obesity, or overweight with a weight-related condition. Because it is a manufactured small molecule (not an injected peptide), it is expected to be easier to scale than injectables. It is also being studied for type 2 diabetes, obstructive sleep apnea and hypertension.

Retatrutide — investigational "triple agonist"

Status: investigational — Phase 3, not FDA-approved. Maker: Eli Lilly. Class: a single molecule that acts on three receptors (GIP, GLP-1 and glucagon).

Retatrutide is the most-watched obesity drug in development. In the Phase 3 TRIUMPH-1 obesity trial (positive topline results announced May 2026), the highest dose produced an average of about 28% body-weight reduction at 80 weeks — among the largest seen in a trial to date. A separate Phase 3 type-2-diabetes trial also met its goals. Eli Lilly has said it expects to complete the program and file with the FDA around late 2026, which would put a possible approval in 2027 at the earliest. These are trial results, not FDA-reviewed labeling, and retatrutide cannot yet be prescribed.

CagriSema — investigational GLP-1 + amylin combination

Status: investigational — FDA application under review (filed December 2025). Maker: Novo Nordisk. Class: a once-weekly injection combining cagrilintide (an amylin analogue) with semaglutide (the GLP-1 drug in Ozempic and Wegovy).

CagriSema pairs two different appetite pathways in one injection. In the Phase 3 REDEFINE 1 trial, participants lost about 23% of body weight on average. Novo Nordisk submitted its FDA application in December 2025; a decision is expected in late 2026 or 2027. It is not yet approved.

Others in development

Several more candidates are in trials, including survodutide (Boehringer Ingelheim / Zealand Pharma; a GLP-1/glucagon dual agonist studied for obesity and liver disease) and higher-dose oral semaglutide for weight management. All remain investigational; details and timing can change.

How these compare to what you can get today

Only the approved medicines can be prescribed now. For those, see our independent, source-backed ratings:

• Foundayo — orforglipron, the new daily oral GLP-1 pill (approved April 2026)
• Ozempic and Wegovy — semaglutide (weekly injection)
• Mounjaro and Zepbound — tirzepatide (weekly injection)
• The full GLP-1 drug class, compared — side by side with our FDA recall-safety rating
• Background on the condition: obesity and what to take for weight loss

Frequently asked

Is there a GLP-1 weight-loss pill? Yes — orforglipron (Foundayo) was FDA-approved in April 2026 as the first daily oral GLP-1 for weight management. Oral semaglutide (Rybelsus) has long existed for type 2 diabetes, with weight-management use developing.

Is retatrutide FDA-approved? No. As of June 2026 retatrutide is investigational (Phase 3); a possible FDA filing is expected around late 2026, so any approval would come later. It cannot be prescribed yet.

Is CagriSema approved? Not yet. Novo Nordisk filed its FDA application in December 2025; a decision is expected in late 2026 or 2027.

Which new drug causes the most weight loss? In trials, retatrutide has shown the largest average reductions (~28% at the top dose), ahead of reported figures for CagriSema (~23%) — but these come from different trials and are not head-to-head, and trial averages are not a promise of individual results. None of this is medical advice; effectiveness, safety and suitability differ by person.

General information only — not medical advice, and not a substitute for talking with a licensed clinician. Investigational drugs are not available by prescription. Sources include FDA approval records and the manufacturers' Phase 3 trial announcements.